Accordingly, we selected IL-8 within the TME for this study, as clinical trials involving IL-8 receptor inhibitors and anti-IL-8 antibodies have been conducted in breast [33] and prostate [34] cancers. The gene discussed is CXCL8; the disease is cancer.